Ovarian cancer vaccines are under development, but none are ready for primetime. There are no screening tools for ovarian ...

The 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...

The EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and ...

Nine years as an ovarian cancer “lifer” yields these tips for surviving and thriving when there’s no end of treatment ahead.

Bianca Muñiz, a three-time cancer survivor first diagnosed at age 11, shared her powerful story on International Childhood ...

Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the ...

THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in advanced ovarian cancer and other solid tumours. Suitable for ...

GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: ...

Researchers from the Walter and Eliza Hall Institute (WEHI)in Australia have found a new way to predict a subset of patients ...

AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...